The Guardian Opinion – Resia Pretorius [Resia Pretorius is the Head of Department and a Distinguished Research Professor in the Physiological Sciences Department, Faculty of Science, Stellenbosch University, South Africa] “One of the biggest failures during the Covid-19 pandemic is our slow response in diagnosing and treating long Covid. As many as 100 million people worldwide already suffer from long Covid. That staggering number will eventually be much higher, if we take into account that diagnoses are still inadequate, and that we still do not know what the impact of Omicron and future variants will be. Patients with long Covid complain of numerous symptoms, the main ones being recurring fatigue and brain fog, muscle weakness, being out of breath and having low oxygen levels, sleep difficulties and anxiety or depression. Some patients are so sick that they cannot work or even walk a few steps. There is possibly also an elevated risk of stroke and heart attacks. One of the biggest sources of concern is that even mild and sometimes asymptomatic initial Covid-19 infection may lead to debilitating, long-term disability. Since early 2020, we and other researchers have pointed out that acute Covid-19 is not only a lung disease, but actually significantly affects the vascular (blood flow) and coagulation (blood clotting) systems. A recent study in my lab revealed that there is significant microclot formation in the blood of both acute Covid-19 and long Covid patients. With healthy physiology, clots may form (for instance, when you cut yourself). However, the body breaks down the clots efficiently by a process called fibrinolysis. In blood from patients with long Covid, persistent microclots are resistant to the body’s own fibrinolytic processes. We found high levels of various inflammatory molecules trapped in the persistent microclots, including clotting proteins like plasminogen, fibrinogen and Von Willebrand factor (VWF), and also Alpha-2 antiplasmin (a molecule that prevents the breakdown of microclots)…”